BARBARA COLE: Open Payments
NPI 1801445671 · NORTH LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,315 in 133 payments from 13 companies in 2025. Trend: 2023 $1,501 · 2024 $2,280 · 2025 $2,315
Food & beverage: $2,315
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $703 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $366 |
| Janssen Biotech, Inc. | 16 | $286 |
| Regeneron Healthcare Solutions, Inc. | 10 | $282 |
| Lilly USA, LLC | 10 | $185 |
| Madrigal Pharmaceuticals | 4 | $91 |
| EVOKE PHARMA, INC. | 4 | $79 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| GENZYME CORPORATION | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 13 | $63 |
Products named: RINVOQ, DUPIXENT, TREMFYA, ENTYVIO, OMVOH, SKYRIZI, EOHILIA, REZDIFFRA.
Industry payments across AR — which companies pay providers there.
